Drug Discovery News and Research

RSS

The drug discovery process begins with recognizing a disease or clinical condition in which there is a lack of adequate medical treatment. Once a potential drug has been identified, pre-clinical research can begin. This process includes several stages; the first of which involves identifying and validating the prospective drug’s target through assay development, high throughput screening, hit identification and finally, lead optimization. Once the pre-clinical process is complete, the newly synthesized drug candidate is selected for future clinical development.

Moffitt researchers reveal a mechanism leading to drug resistance in prostate cancer

Prostate cancer is the most common cancer among men in the United States. Many patients can live long lives due to early detection and treatment with androgen deprivation therapy.

16 Jun 2022

AKT inhibitor miransertib could be a promising new treatment against low-flow vascular malformations

A team of researchers led by Dr. Sandra Castillo and Dr. Mariona Graupera, from the Josep Carreras Leukaemia Research Institute and member of the CIBERONC, have found the AKT inhibitor miransertib could be a new molecular treatment effective against low-flow vascular malformations, a long-awaited milestone.

14 Jun 2022

Orbit Discovery awarded Innovate UK grant to expand high throughput cell-based functional screening platform capabilities in peptide drug discovery

Orbit Discovery Ltd., (“Orbit”) a privately held biopharmaceutical company focused on discovering candidate peptide therapeutics harnessing proprietary affinity and cell-based functional screening platforms, has been awarded a Smart grant by Innovate UK, the UK’s innovation agency.

From Orbit Discovery 14 Jun 2022

Potential applications of bioactive molecules present in fruit peels

A recent study published in Current Issues in Molecular Biology reviewed the potential biological applications of fruit peel extracts.

13 Jun 2022

Metrion Biosciences appoints Dr Benedetta Montagnini as Head of European Business Development

Metrion Biosciences Limited (“Metrion”), the specialist ion channel contract research and drug discovery company, today announced the appointment of Dr Benedetta Montagnini as Head of European Business Development. Driven by the uptake of its ion channel discovery services, the appointment follows the recent creation of a Client Services team as Metrion expands its operations and enhanced drug discovery capabilities, internationally.

From Metrion Biosciences Limited 9 Jun 2022

Insilico Medicine plans to launch a fully automated AI-driven robotics lab for drug discovery

Insilico Medicine's end-to-end AI-driven drug discovery platform, Pharma.AI, draws its strength from the quality and quantity of its data. As Insilico scientific advisory board member and Nobel Prize laureate in chemistry Dr. Michael Levitt has said, Insilico's platform capitalizes on the ability of artificial intelligence to take vast amounts of data from many different components and find patterns and make predictions that can point the way to new life-saving medications.

9 Jun 2022

Immune protein could be a target of future treatments for alcohol use disorder

The anxiety that occurs during withdrawal from excessive alcohol use, and contributes to relapse, may be driven in part by the release of an immune protein in the brain, according to a new study from scientists at Scripps Research.

8 Jun 2022

Axol Bioscience introduces CiPA-validated human stem cell-derived ventricular cardiomyocytes to help improve drug discovery

Axol Bioscience Ltd. (Axol), an established provider of iPSC-derived cells, media, and characterization services for life science discovery, today announced that its human induced pluripotent stem cell (iPSC)-derived ventricular cardiomyocytes have undergone comprehensive in vitro pro-arrhythmia assay (CiPA) validation.

From Axol Bioscience Ltd 8 Jun 2022

Curia Adopts the Berkeley Lights Platform to Expand its Antibody Discovery Capabilities

Berkeley Lights, Inc. (Nasdaq: BLI), a leader in digital cell biology, and Curia, formerly AMRI, a leading contract research, development and manufacturing organization (CDMO), today announced Curia’s adoption of The Beacon® Optofluidic system and workflows from Berkeley Lights to accelerate and expand its antibody-based drug discovery capabilities.

From Bruker Cellular Analysis 6 Jun 2022

Researchers repurpose a cancer drug for the treatment of neuroinflammatory diseases

The repurposing of FDA-approved drugs for alternative diseases is a faster way of bringing new treatments into the clinic.

3 Jun 2022

Novel approach identifies potent drug-like molecules that bind to cancer protein of interest

Researchers at Baylor College of Medicine and Texas Children's Hospital have identified potent, highly specific compounds that interfere with bromodomain (BD)-containing proteins involved in cancer.

3 Jun 2022

New method to combat malaria turns the disease against itself

A new method to combat malaria which sees the disease turn against itself could offer an effective treatment for the hundreds of millions of people infected globally each year, as the efficacy of current antimalarial drugs weakens.

3 Jun 2022

Collaborative effort uncovers a new type of triterpenes

A remarkable discovery and collaborative effort have revealed a new type of triterpenes, a group of organic compounds which are an important source of many medicines.

1 Jun 2022

Innovative solutions to the challenges of narcotic analysis

In this interview, Dr. Joerg Koehler and Dr. Marcio-Fernando Cobo from Bruker introduce their forensic distributed lab topology featuring the Fourier 80 CrimeLab with NMR-based narcotics profiling module.

From Bruker BioSpin Group 30 May 2022

Dr. Paul Brooks is CN Bio's New Chief Business Officer

CN Bio, a leading Organ-on-a-chip Company (OOC) that designs and manufactures single- and multi-organ microphysiological systems (MPS), today announced the appointment of Dr. Paul Brooks as Chief Business Officer.

From CN Bio 25 May 2022

Insilico Medicine nominates novel preclinical candidate targeting 3CL protease for COVID-19 treatment

Insilico Medicine, a clinical-stage end-to-end artificial intelligence (AI)-driven drug discovery company, today announced its nomination of a novel preclinical candidate (PCC) targeting 3C-like (3CL) protease for the treatment of COVID-19.

24 May 2022

Researchers discover osteogenetic oligodeoxynucleotide that promotes bone differentiation

Bone tissue homeostasis is maintained by a balance between bone formation by osteoblasts and bone resorption by osteoclasts.

23 May 2022

University of Minnesota receives $66 million to establish new antiviral drug discovery center

The University of Minnesota has received $66 million from the National Institute of Allergy and Infectious Diseases to establish a center to develop antiviral drugs for pandemic-level viruses, including SARS-CoV-2.

23 May 2022

UNC-Chapel Hill secures $65 million NIH grant for establishing Antiviral Drug Discovery Center

The National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health awarded the UNC Gillings School of Global Public Health a $65 million grant establishing an Antiviral Drug Discovery Center to develop oral antivirals that can combat pandemic-level viruses like COVID-19.

20 May 2022

New funding boost to combat antibiotic resistance

Antibiotics have saved countless lives since they were introduced in the 1940s, curing infections and making procedures like chemotherapy and surgeries safer. But their effectiveness is waning.

19 May 2022

Drug Discovery News and Research

Further Reading

Moffitt researchers reveal a mechanism leading to drug resistance in prostate cancer

AKT inhibitor miransertib could be a promising new treatment against low-flow vascular malformations

Orbit Discovery awarded Innovate UK grant to expand high throughput cell-based functional screening platform capabilities in peptide drug discovery

Potential applications of bioactive molecules present in fruit peels

Metrion Biosciences appoints Dr Benedetta Montagnini as Head of European Business Development

Insilico Medicine plans to launch a fully automated AI-driven robotics lab for drug discovery

Immune protein could be a target of future treatments for alcohol use disorder

Axol Bioscience introduces CiPA-validated human stem cell-derived ventricular cardiomyocytes to help improve drug discovery

Curia Adopts the Berkeley Lights Platform to Expand its Antibody Discovery Capabilities

Researchers repurpose a cancer drug for the treatment of neuroinflammatory diseases

Novel approach identifies potent drug-like molecules that bind to cancer protein of interest

New method to combat malaria turns the disease against itself

Collaborative effort uncovers a new type of triterpenes

Innovative solutions to the challenges of narcotic analysis

Dr. Paul Brooks is CN Bio's New Chief Business Officer

Insilico Medicine nominates novel preclinical candidate targeting 3CL protease for COVID-19 treatment

Researchers discover osteogenetic oligodeoxynucleotide that promotes bone differentiation

University of Minnesota receives $66 million to establish new antiviral drug discovery center

UNC-Chapel Hill secures $65 million NIH grant for establishing Antiviral Drug Discovery Center

New funding boost to combat antibiotic resistance

Event guide: The 5th ALS Drug Development Summit eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo